Demethylation in different regions of the hMLH1 promoter after 5-aza-2′-deoxycytidine treatment
| Cell line . | Demethylation extenta in different regions . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | Ab . | B . | C . | D . | |||
| C1a | 4% | 23% | 40% | 40% | |||
| VACO5 | 22% | 17% | 19% | 24% | |||
| RKO | 0% | 1% | 29% | 29% | |||
| C | 29% | 32% | 33% | 29% | |||
| Cell line . | Demethylation extenta in different regions . | . | . | . | |||
|---|---|---|---|---|---|---|---|
| . | Ab . | B . | C . | D . | |||
| C1a | 4% | 23% | 40% | 40% | |||
| VACO5 | 22% | 17% | 19% | 24% | |||
| RKO | 0% | 1% | 29% | 29% | |||
| C | 29% | 32% | 33% | 29% | |||
The extent of demethylation was calculated by averaging the percentage of meth-ylation of all CpG sites in the region before 5-aza-2′-deoxycytidine treatment subtracted by the average percentage of methylation after treatment. The concentrations of 5-aza-2′-deoxycytidine used to treat cell lines C1a, VACO5, RKO, and C were 5, 15, 10, and 5 μm, respectively.
Regions A, B, C, and D are the same as in Table 1.